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Medical Marijuana and Pharmacy Practice
Abstract
By way of the Compassionate Care Act of 2014, New York has become the 23rd state to create a process
that will permit patients suffering from a “serious condition” to receive medical marijuana (or “cannabis”).
Among those, it is the second state to prohibit the crude delivery system of smoking (Minnesota), and the
third to involve pharmacists in the dispensing process (Connecticut and Minnesota). Because virtually
every practicing pharmacist in New York will be caring for patients receiving some form of cannabinoid
therapy, it is important to discuss the basic outlines established by the law and regulations.
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Medical Marijuana and Pharmacy Practice

Karl G. Williams, RPh, LLM, JD, W egman’s School of Pharmacy/St. John’s Fisher

By way of the Compassionate
Care Act of 2014, New York has
become the 23rd state to create a
process that will permit pa ents
suﬀering from a “serious condi on”
to receive medical marijuana (or
“cannabis”). Among those, it is the
second state to prohibit the crude
delivery system of smoking
(Minnesota), and the third to
involve
pharmacists
in
the
dispensing process (Connec cut
and Minnesota). Because virtually
every prac cing pharmacist in New
York will be caring for pa ents
receiving some form of cannabinoid
therapy, it is important to discuss
the basic outlines established by
the law and regula ons.
The Act provided for the basic
policies and framework for the
pa ent care process, product
development,
and
product
distribu on. Also, the Act gave the
Department of Health (“DoH”)
authority to write regula ons to
further clarify specific details that
are necessary for safe, secure, and
responsible implementa on of this
therapy. The DoH regula ons were
finalized and published on April 15,
2015 and published in Title 10 of
New York’s Code of Rules and
Regula ons.

Pa ents may receive medical
cannabis if a properly qualified physician concludes that the pa ent
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will realize a “therapeu c or
pallia ve benefit” for one of ten
listed serious condi ons. The list
includes the following:
x Cancer
x HIV/AIDS

x ALS
x Parkinson’s disease
x Mul ple sclerosis
x Spinal cord damage exhibi ng

intractable spas city
x Epilepsy
x Inflammatory bowel disease
x Neuropathies
x Hun ngton’s disease

Also, cachexia, severe or chronic
pain, severe nausea, seizures, and
muscle spasms, associated with any
of the listed diseases. In addi on,
the Commissioner, in his discre on,
may add Alzheimer’s disease,
muscular dystrophy, dystonia, posttrauma c stress disorder, and
rheumatoid arthri s within eighteen months of the eﬀec ve date of
the law; that is January 2016.
As men oned, smoking is not
an approved medica on delivery
system under the Compassionate
Care Act. The regula ons specify
that the following are permissible:
liquid or oils for oromucosal use,
metered oil/liquid for vaporiza on,
and
capsules
for
oral
administra on.
Edible
food
products
are
not
currently
permi ed in the regula ons. The

Commissioner
may
approve
addi onal formula ons at a later
me.
A physician who treats one or
more of these condi ons, and has
registered with DoH to provide this
therapy, may issue a “cer fica on”
for primary or adjunc ve treatment
if, in his or her “professional
opinion”, the pa ent will benefit.
No ce that the cer fica on is not a
prescrip on in the tradi onal
sense. Prescrip on has a discrete
defini on under the Code of
Federal regula ons, and inconsistent with its use in ordering a
Schedule I controlled substance. It
is perhaps be er to view the
cer fica on as an alternaƟve to the
prescrip on. Like a prescrip on, the
prac oner is directed to consider
the form of cannabis, route of
administra on, par cular strain,
variety, quan ty, dosage, and any
limita ons on therapy. Also, the
cer fying physician (or a designee)
is required to review the
prescrip on monitoring program
(or “PMP”, as established in the
iSTOP law) registry prior to
cer fica on for the “purpose of
reviewing a pa ent’s controlled
substance history”.
Once cer fied by the physician,
pa ents must then submit an
applica on to the DoH for a registry
ID card enabling the acquisi on,
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lawful possession, and use of a
specified product for a maximum
30-day supply. Also, the law
provides for registra on of
“designated caregivers” who may
assist pa ents in this process. This
may include picking up the
medica on from the dispensary,
assistance with dosing, and
temporary possession as long as
the caregiver has registered and
has an oﬃcial ID card. The registry
ID card expires one year from the
date the cer fica on is signed by
the physician unless the pa ent is
terminally ill, in which case the
physician
may
specify
that
cer fica on will terminate on the
death of the pa ent.

Medical cannabis will be
supplied
by
“registered
organiza ons” that have been
approved by the DoH. Each of five
registered organiza ons will be
integrated
(“seed-to-sale”)
to
cul vate, formulate products, and
dispense to registered pa ents or
caregivers.
Each
“registered
organiza on” is permi ed to
operate four dispensaries, located
separately from the produc on
facili es, in various loca ons
around the state. The dispensaries
will be located in the following
coun es: Nassau, New York (2),
Onondaga (3), Erie (2), Suﬀolk,
Clinton, Monroe, Broome, Albany
(3), Westchester (2), Queens,
Ulster, and Bronx.
On receipt of a proper registry
ID card, dispensary personnel

(unlike pharmacies) are required to
check the PMP registry to ensure
that the pa ent will not have more
than a 30-day supply with a 7-day
grace period. That is, the pa ent
may receive a refill within seven
days of the me the previous
supply would be exhausted. This is
the same standard followed by
community
pharmacists
for
controlled substances. In addi on,
dispensary personnel will a ach a
pa ent-specific label to the
unopened package that includes
x Name and registry ID number

of the pa ent (and designated
caregiver, if any);
x Cer fying physician;
x Dispensing
facility name,
address, and phone number;
x Dosing and administra on
instruc ons;
x Quan ty and date dispensed;
and
x Any
recommenda on or
limita on as to use of the
medica on.
Also, at the me of dispensing,
a safety insert shall be provided
which will include informa on on
administra on methods, poten al
dangers associated with use, how
to recognize problem usage and
obtain appropriate treatment, and
other relevant informa on. Finally,
the dispensary is required to, within
24 hours, report dispensed
products to the DoH. This is similar
to any controlled substance
delivered to/for a pa ent in the
pharmacy context. This step will
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provide the informa on that,
among other things will populate
the PMP.
Impact on Pharmacy Prac ce
Given the noted similari es to
community
pharmacies
(and
perhaps contrary to intui on), it is
important to state explicitly that
dispensaries are not pharmacies.
Unlike pharmacies that are
regulated by the Department of
Educa on, dispensaries are licensed
and regulated by the Department
of Health. An interes ng provision
in the law reads: “Medical
marihuana shall not be deemed to
be a “drug” for the purposes of
ar cle one hundred thirty-seven of
the educa on law”. This would
seem to limit regula on by the
Board of Pharmacy/Department of
Educa on and cements DoH as the
sole
regulatory
authority
concerning the organiza on and
products. Also, dispensaries are
permi ed to distribute only medical
cannabis products and associated
administra on devices, unless other
products are specifically approved
by the department.
Dispensaries will be similar to
pharmacies in many ways that are
extremely important to the profession. Perhaps chief among those is
that “dispensing facili es shall not
be open or in opera on unless an
individual with an ac ve New York
state pharmacist license…is on
premises and directly supervising
the ac vity within the facility”. That
(ConƟnued on page 12)
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(ConƟnued from page 18)

is, each dispensary will require a
supervising pharmacist to ensure
the integrity of the dispensing
process
and,
presumably,
management of the inventory. This
language is general enough to imply
the need for authority to control
processes, because there will surely
be accountability if something goes
wrong.
In addi on to the supervisory
role, there is an implicit clinical role
for the pharmacist provided in the
regula ons. Sec on 1004.21(d)
provides that no employee shall
“counsel…on the use, administra on of, and the risks…unless…a
pharmacist…or under the direct
supervision of…the pharmacist
on-site in the dispensing facility.”
The pharmacists must complete a
four-hour training program approved by the commissioner. Since
the unprofessional conduct rules of
the Board of Regents prohibit delega on of counseling to any unlicensed
person,
counseling
(properly) must be conducted by a
pharmacist or an intern. Among
other things this implies the
maintenance of an accurate
medica on profile and counseling
as provided for in the pharmacy
regula ons.
Liability
The threat of legal risk at the
hands of the federal government
has been the subject of recent
specula on. Pharmacists may well
recall the 2005 case of Gonzales v.
Raisch where the US Supreme Court
aﬃrmed the authority of the
federal government to intervene
into a state’s medical cannabis
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process, despite even the slimmest
eﬀect on interstate commerce.
Indeed, as clearly discussed in
“Marijuana – Medical or??”, in the
Fourth Quarter 2014 Edi on of the
New York State Pharmacist, the
federal government is currently
exercising
“enforcement
discre on”. That is, the US
Department of Jus ce has publicly
stated that it will con nue in this
policy as long as states making
cannabis available to its ci zens
exercise a high level of integrity in
the process
through
“strict
regulatory schemes”. Given New
York’s highly regulated process, and
given the emerging understanding
of the importance of cannabis in
pa ent care, federal liability has
become extremely remote for New
York’s pharmacists.
Conclusions
Pharmacists in clinical prac ce
in New York, regardless of the
nature of the prac ce, will be in a
posi on to ensure that pa ents
receiving medical cannabis therapy
will receive op mal care. Indeed,
there is a legal and moral
obliga on to become adequately prepared to provide this care. Most directly
for those prac cing in a
dispensary, it will be
necessary to obtain a complete pa ent medica on
profile for the purpose of
prospec ve review for contraindica ons, drug-drug
interac ons, and other poten al drug therapy prob-

lems that may be addressed during
counseling. Although it will not be
dispensed in the hospital environment, community prac ce, or longterm care se ng, pharmacists will
need to be aware of the fact of cannabinoid therapy for essen ally the
same reasons. Consistent with this,
we will need to educate ourselves
about cannabinoids to aﬀect
pa ent care.
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